The effects of the EZH2 inhibitor were anti-proliferative, as demonstrated by the retardation of tumor growth (Figure 7a and b) associated to a reduction of the proliferative marker Ki67 in tumor xenografts (Figure 7c, left panel), and led to de novo expression of fibers positive for Myosin Heavy Chain (MHC) compared to vehicle treatment (Figure 7c, right panel). This evidence concerns the gene HLA-C and neoplasm.